Profile data is unavailable for this security.
About the company
Otsuka Holdings Co., Ltd. is a Japan-based company mainly engaged in the medical and nutraceuticals related business and other businesses. The Company operates through four business segments. The Medical-related segment is engaged in the sale of ethical drugs, and the research development and export of therapeutic drugs. The Nutraceuticals-related segment is engaged in the manufacture, purchase and sale of nutraceuticals-related products, such as functional food and dietary supplements. The Consumer-related segment is engaged in the manufacture and sale of consumer products and mineral water. The Others segment is engaged in the manufacture and sale of chemical products, the manufacture, sale and import of measuring equipment, and the manufacture of synthetic resin molding products.
- Revenue in JPY (TTM)2.27tn
- Net income in JPY151.58bn
- Incorporated2008
- Employees34.39k
- LocationOtsuka Holdings Co LtdShinagawa Grand Central Tower2-16-4, KonanMINATO-KU 108-8241JapanJPN
- Phone+81 367171410
- Fax+81 367171409
- Websitehttps://www.otsuka.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin Co Ltd | 498.98bn | 83.53bn | 1.33tn | 5.97k | 16.11 | 1.59 | 12.28 | 2.66 | 156.64 | 156.64 | 936.10 | 1,591.79 | 0.4878 | 1.78 | 3.92 | 83,524,780.00 | 8.17 | 6.28 | 9.50 | 7.08 | 74.30 | 75.45 | 16.74 | 14.96 | 3.06 | -- | 0.0276 | 47.25 | 11.01 | 10.25 | 51.55 | 10.52 | 10.28 | 9.86 |
| Eisai Co Ltd | 753.22bn | 40.97bn | 1.38tn | 11.07k | 32.44 | 1.60 | 16.70 | 1.83 | 143.36 | 143.36 | 2,634.81 | 2,905.11 | 0.5673 | 0.8933 | 3.89 | 68,060,180.00 | 3.21 | 5.29 | 4.32 | 7.16 | 79.12 | 76.91 | 5.67 | 8.68 | 1.50 | -- | 0.1781 | 74.13 | -0.3561 | 2.90 | -23.50 | -7.72 | -2.11 | 1.30 |
| Shionogi & Co Ltd | 418.51bn | 154.57bn | 1.86tn | 4.96k | 11.59 | 1.38 | 10.77 | 4.45 | 180.74 | 180.74 | 489.15 | 1,519.70 | 0.292 | 0.9189 | 2.94 | 84,393,830.00 | 10.69 | 12.57 | 11.94 | 14.24 | 85.70 | 84.43 | 36.62 | 37.91 | 6.48 | -- | 0.0088 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
| Astellas Pharma Inc | 1.77tn | 54.75bn | 2.83tn | 14.75k | 51.35 | 1.83 | 11.28 | 1.60 | 30.42 | 30.42 | 986.34 | 854.61 | 0.5060 | 1.36 | 3.39 | 120,113,500.00 | 1.56 | 4.59 | 2.31 | 6.61 | 81.78 | 80.53 | 3.09 | 7.98 | 0.8623 | 15.32 | 0.3774 | 86.61 | 5.60 | 4.19 | -82.73 | -40.17 | 9.62 | 13.00 |
| Otsuka Holdings Co Ltd | 2.27tn | 151.58bn | 4.97tn | 34.39k | 31.88 | 1.92 | 18.89 | 2.19 | 279.51 | 279.51 | 4,183.34 | 4,641.15 | 0.647 | 2.40 | 4.68 | 65,998,690.00 | 4.42 | 4.80 | 5.59 | 5.88 | 71.42 | 68.21 | 6.84 | 8.36 | 1.53 | -- | 0.1173 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| Takeda Pharmaceutical Co Ltd | 4.55tn | 289.99bn | 6.54tn | 49.28k | 22.61 | 0.9421 | 6.24 | 1.44 | 181.90 | 181.90 | 2,862.68 | 4,365.91 | 0.3088 | 1.31 | 6.25 | 92,248,190.00 | 1.97 | 1.65 | 2.35 | 1.97 | 66.05 | 68.05 | 6.38 | 6.06 | 0.7739 | 3.08 | 0.4219 | 128.42 | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | 0.8735 |
| Daiichi Sankyo Co Ltd | 1.76tn | 250.40bn | 8.64tn | 18.73k | 33.89 | 5.18 | 27.41 | 4.91 | 130.86 | 130.86 | 918.60 | 855.86 | 0.5913 | 1.01 | 3.73 | 93,883,960.00 | 8.43 | 4.99 | 10.51 | 6.14 | 76.11 | 69.10 | 14.26 | 9.94 | 2.24 | -- | 0.0589 | 51.87 | 25.28 | 11.49 | 85.90 | 16.67 | 13.01 | 16.47 |
| Chugai Pharmaceutical Co Ltd | 1.14tn | 386.96bn | 10.53tn | 7.60k | 26.66 | 5.73 | -- | 9.22 | 235.14 | 235.14 | 694.16 | 1,094.71 | 0.5877 | 1.22 | 3.56 | 150,230,100.00 | 19.91 | 19.29 | 22.95 | 23.91 | 70.48 | 63.57 | 33.87 | 28.39 | 4.80 | -- | 0.00 | 40.14 | -11.78 | 13.90 | -13.08 | 28.61 | -0.8947 | 27.23 |
Data as of Nov 22 2024. Currency figures normalised to Otsuka Holdings Co Ltd's reporting currency: Japanese Yen JPY
21.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 13 Sep 2024 | 26.28m | 4.71% |
| BlackRock Fund Advisorsas of 31 Mar 2023 | 17.37m | 3.11% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 16.21m | 2.91% |
| Nikko Asset Management Co., Ltd.as of 08 Nov 2024 | 12.46m | 2.23% |
| Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 11.79m | 2.11% |
| Wellington Management Co. LLPas of 31 Oct 2024 | 10.88m | 1.95% |
| BlackRock Japan Co. Ltd.as of 31 Mar 2023 | 9.69m | 1.74% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 6.62m | 1.19% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Nov 2024 | 6.30m | 1.13% |
| Geode Capital Management LLCas of 21 Nov 2024 | 4.95m | 0.89% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
